Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Clinical Trials
6
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2014
Active, not recruiting
4
66.7%
Terminated
2
33.3%
No approval data available
- MaxCyte has entered a multi-platform technology license agreement with Genentech, a Roche Group member, to support cell therapy programs from discovery through cGMP manufacturing. - The non-exclusive license provides Genentech access to MaxCyte's ExPERT GTx platform and flow electroporation technology for ex vivo cell engineering without viral vectors. - The agreement spans multiple internal Genentech programs rather than a single therapeutic candidate, though specific programs and financial terms were not disclosed. - This partnership expands Genentech's cell therapy manufacturing capabilities as Roche continues building its presence in the field, following its late-2024 acquisition of Poseida Therapeutics.
- Roche has deployed over $15 billion in upfront capital across roughly two years to enter obesity, inflammatory bowel disease, allogeneic cell therapy, and neurodegeneration, marking a strategic pivot beyond its traditional oncology base. - The company's TL1A antibody afimkibart, acquired via the $7.1 billion Telavant deal, faces intensified competition after Merck's tulisokibart delivered the first positive phase 3 results in ulcerative colitis in June 2026. - Roche's obesity strategy centers on CT-388, a dual GLP-1/GIP agonist showing 22.5% placebo-adjusted weight loss at 48 weeks, combined with Zealand Pharma's amylin analog petrelintide in a $5.3 billion collaboration. - The Poseida Therapeutics acquisition provides Roche an allogeneic CAR-T platform, with lead candidate P-BCMA-ALLO1 demonstrating a 91% overall response rate in heavily pretreated multiple myeloma patients.
- MBX Biosciences appointed Karen Basbaum as Chief Business Officer, bringing over two decades of experience in biotechnology business development and strategic transactions. - Basbaum previously led strategic partnerships worth over $10 billion in potential value at Poseida Therapeutics and played a key role in the company's $1.5 billion sale to Roche. - The appointment comes as MBX advances its peptide therapy pipeline, including canvuparatide preparing for Phase 3 development for chronic hypoparathyroidism. - MBX's proprietary PEP platform focuses on developing precision peptide therapies for endocrine and metabolic disorders with significant unmet medical needs.
- ImageneBio announced a protocol amendment for its ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis to optimize study design and expand dosing regimens based on the drug's unique molecular attributes. - The company will present novel alopecia areata data at the Inflammatory Skin Disease Summit, showing dose-related hair regrowth and biomarker suppression in Phase 1b/2a trials. - IMG-007 demonstrated a 77% mean reduction in EASI score at week 16 in atopic dermatitis patients, with 54% achieving EASI-75 response and 31% reaching EASI-90 response. - The company strengthened its cash position to $142.6 million following completion of a reverse merger and $75 million private placement financing.
- Our Lady of the Lake Cancer Institute becomes the first site in Louisiana to participate in a Phase I clinical trial evaluating allogeneic CAR-T cell therapy for cancer treatment. - The innovative study utilizes donor-derived T cells that are genetically engineered to recognize and target cancer cells, potentially leading to reduced treatment durations and enhanced patient outcomes. - Dr. Nakhle Saba serves as the principal investigator for this cellular immunotherapy study, while the institute has also recruited Dr. Harry Sequeira to strengthen its cell therapy capabilities. - The clinical trial is conducted in partnership with Poseida, representing a significant advancement in personalized immunotherapy that trains immune cells to recognize and destroy cancer.
- Wugen raised $115 million in financing led by Fidelity Management & Research to advance its pivotal T-RRex trial of WU-CART-007, an off-the-shelf CAR-T therapy for relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. - WU-CART-007 demonstrated exceptional efficacy in Phase 1/2 trials with a 91% overall response rate and 73% complete remission rate, substantially outperforming current standard-of-care therapies for these aggressive malignancies. - The company aims to file a Biologics License Application in 2027, positioning WU-CART-007 as the potential first approved allogeneic CAR-T therapy for T-cell malignancies. - The therapy uses CRISPR gene editing technology and donor-derived cells to create an accessible, scalable treatment that eliminates the need for patient-specific cell extraction and manipulation.
- Ikena Oncology and Inmagene Biopharmaceuticals have appointed former Poseida Therapeutics CEO Kristin Yarema to lead the merged company ImageneBio following their anticipated July 2025 closing. - The merger includes a concurrent $75 million private placement and will focus on advancing IMG-007, an anti-OX40 monoclonal antibody that recently completed Phase 2a trials in atopic dermatitis and alopecia areata. - IMG-007 demonstrated sustained clinical activity with a 34.7-day half-life in subcutaneous formulation, supporting potential for infrequent dosing in immunological and inflammatory diseases.
• Roche Holding's MUSETTE Phase III trial demonstrated strong efficacy of the approved 600 mg dose of OCREVUS for multiple sclerosis, reinforcing its position in the treatment landscape. • The company has launched a new subcutaneous formulation of OCREVUS, expanding administration options for patients while continuing to build its neuromuscular disease portfolio. • Roche has outperformed both the Swiss market and pharmaceutical industry with a 33.01% total shareholder return over the past year, bolstered by strategic collaborations and regulatory approvals.
• A comprehensive review of global clinical trials for relapsed multiple myeloma (R/R MM) reveals key trends in trial locations, phases, and sponsor types. • The analysis identifies prominent drugs under investigation and highlights recent clinical trial news, including updates from ASH 2024 and other major meetings. • The review emphasizes the importance of understanding trial enrollment trends and success rates to inform business strategies and identify key opportunities in the R/R MM therapeutics market. • Recent data showcases promising results for novel combinations and CAR-T cell therapies, suggesting potential breakthroughs in treating R/R MM.
• Roche acquired Poseida Therapeutics for US$1.5 billion, signaling strong interest in cell therapy, particularly allogeneic approaches for blood cancers. • Arovella Therapeutics (ALA) is preparing to commence Phase 1 trials in 2025 with its iNKT cell therapy platform, targeting CD19-expressing blood cancers. • ALA's early preclinical data demonstrates promising results, including spontaneous secondary remission in mice, suggesting potential long-term efficacy. • ALA has strengthened its clinical advisory board with the appointment of Professor Sattva Neelapu, an expert in CAR-T therapy development and FDA approval.
